Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EFZT | ISIN: SE0020181014 | Ticker-Symbol: MVR0
Frankfurt
28.03.24
21:50 Uhr
0,219 Euro
-0,003
-1,26 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIVIR AB Chart 1 Jahr
5-Tage-Chart
MEDIVIR AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,1980,27828.03.

Aktuelle News zur MEDIVIR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.03.Medivir to present at Swiss Nordic Bio in Zürich on March 72
04.03.Medivir to present at the Life Science Day in Gothenburg on March 61
26.02.Change in Medivir's nomination committee before the 2024 AGM1
22.02.Medivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer Summit98STOCKHOLM, Feb. 22, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need...
► Artikel lesen
19.02.Medivir's CEO comments on the latest developments2
15.02.Medivir AB - Year-end Report January - December 202386STOCKHOLM, Feb. 15, 2024 /PRNewswire/ -- "The clinical efficacy of fostrox in combination with Lenvima continues to improve with median time to progression having increased to over 6 months" October...
► Artikel lesen
31.01.Improved clinical data and new shareholder strengthen Medivir1
31.01.Medivir reports share and vote count increase after issues2
31.01.Number of shares and votes in Medivir AB on 31 January 20241
26.01.Medivir announces the outcome of the directed share issue which was announced on 22 January 20241
24.01.Medivir to present at the Redeye Fight Cancer Day1
23.01.Medivir reports progress in liver cancer treatment study3
23.01.Medivir invites to a conference call today on updated data at ASCO GI and the plans moving forward for fostrox in primary liver cancer (HCC)2
22.01.Medivir carries out a directed share issue of approx. SEK 20 million2
17.01.Medivir reports progress in liver cancer study3
17.01.MEDIVIR: Fostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI Symposium1
15.01.Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit further supporting the continued development of fostrox2
04.01.Nasdaq Stockholm AB: Delisting of paid subscription shares (BTA) in Medivir AB (1/24)341The paid subscription shares in Medivir AB will be delisted . Instrument: Paid subscription shares --------------------------------------- Short name: MVIR BTA --------------------------------------- ISIN...
► Artikel lesen
04.01.Medivir's licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study158STOCKHOLM, Jan. 4, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need...
► Artikel lesen
22.12.23Medivir announces the outcome of the rights issue5
Seite:  Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1